RxDoctor Payments Data

Timothy Schmidt, MD

Hematology & Oncology · Madison, WINPI 1598182974

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,620 of the $19,059 with a category attached, or 61.0%. Sanofi accounts for 69.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $9,338 and has fallen 84.3% since, to $1,466 in 2024.

$19,059in general payments, 2019–2025

Across 17 payments — averaging $1121.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$13K
  • Janssen Scientific Affairs, LLC$3K
  • Pfizer$1K
  • Johnson & Johnson$1K
  • AstraZeneca$135
  • Adaptive Biotechnologies Corporation$64
$1,227,501in research payments, 2019–2025

Across 56 payments — averaging $21,920 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$807K
  • AstraZeneca$196K
  • Bristol Myers Squibb$178K
  • Pfizer$35K
  • E.r. Squibb & Sons, L.L.C.$11K

What the payments were for

  • Consulting fees$11,62061%
  • Speaking & faculty fees$6,17532%
  • Travel & lodging$5723%
  • Food & beverage$6924%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,059 in reported general payments places this provider in the 85th percentile of 248 hematology & oncology providers in Wisconsin.

See all hematology & oncology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$63,268
Medicare patients
178
Services billed
819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide143$2,482,720
Lenalidomide118$1,390,942
PomalystPomalidomide33$660,638
VenclextaVenetoclax11$150,645
ZarxioFilgrastim-Sndz24$61,578
EliquisApixaban28$21,160
Acyclovir238$4,064
ShingrixVaricella-Zoster Ge/As01b/Pf12$2,537
Menveo A-C-Y-W-135-DipMening Vac A,c,y,w-135 Dip/Pf13$2,369
PentacelDipht,pert(A),tet-Polio/Hib/Pf12$1,584
Dexamethasone91$968
Duloxetine Hcl31$803
Ondansetron Hcl45$553
Colestipol Hcl12$546
Potassium Chloride25$546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,330$21,16028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 248 hematology & oncology providers in Wisconsin.

Other hematology & oncology in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →